Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors.

Wetherill LF, Holmes KK, Verow M, Müller M, Howell G, Harris M, Fishwick C, Stonehouse N, Foster R, Blair GE, Griffin S, Macdonald A.

J Virol. 2012 May;86(9):5341-51. doi: 10.1128/JVI.06243-11. Epub 2012 Feb 22.

2.

Mutation of a C-terminal motif affects Kaposi's sarcoma-associated herpesvirus ORF57 RNA binding, nuclear trafficking, and multimerization.

Taylor A, Jackson BR, Noerenberg M, Hughes DJ, Boyne JR, Verow M, Harris M, Whitehouse A.

J Virol. 2011 Aug;85(15):7881-91. doi: 10.1128/JVI.00138-11. Epub 2011 May 18.

3.

Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.

Foster TL, Verow M, Wozniak AL, Bentham MJ, Thompson J, Atkins E, Weinman SA, Fishwick C, Foster R, Harris M, Griffin S.

Hepatology. 2011 Jul;54(1):79-90. doi: 10.1002/hep.24371.

PMID:
21520195
4.

Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability.

Carter SD, Dent KC, Atkins E, Foster TL, Verow M, Gorny P, Harris M, Hiscox JA, Ranson NA, Griffin S, Barr JN.

FEBS Lett. 2010 Jul 2;584(13):2786-90. doi: 10.1016/j.febslet.2010.05.006. Epub 2010 May 20.

5.

Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro.

StGelais C, Foster TL, Verow M, Atkins E, Fishwick CW, Rowlands D, Harris M, Griffin S.

J Virol. 2009 Aug;83(16):7970-81. doi: 10.1128/JVI.00521-09. Epub 2009 Jun 3.

Supplemental Content

Support Center